Search results
Showing 1216 to 1230 of 9025 results
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.
Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
NICE is unable to make a recommendation about the use in the NHS of regorafenib for metastatic colorectal cancer after treatment for metastatic disease. This is because Bayer did not provide an evidence submission.
Show all sections
Sections for TA334
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
NICE is unable to make a recommendation about the use in the NHS of canakinumab for systemic juvenile idiopathic arthritis. This is because Novartis did not provide an evidence submission.
Show all sections
Sections for TA302
Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.
Evidence-based recommendations on anhydrous sodium thiosulfate (Pedmarqsi) for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours.
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA1047
Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)
NICE is unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma. This is because Bristol–Myers Squibb did not provide an evidence submission.
Show all sections
Sections for TA434
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.